170 related articles for article (PubMed ID: 31857109)
1. CADM1: A molecule worth investigating in mycosis fungoides and Sézary syndrome.
Zhang S; Wang T; Liu Y
J Am Acad Dermatol; 2020 Apr; 82(4):e141-e142. PubMed ID: 31857109
[No Abstract] [Full Text] [Related]
2. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
3. New options in diagnosis and management of mycosis fungoides and Sézary syndrome.
Enke CA
Oncology (Williston Park); 2010 May; 24(6):507-8. PubMed ID: 20568591
[No Abstract] [Full Text] [Related]
4. Recent developments in the early diagnosis of mycosis fungoides and Sézary's syndrome.
Willemze R
Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1581-3. PubMed ID: 3428330
[No Abstract] [Full Text] [Related]
5. [T cell subsets and nuclear contour index of skin-infiltrating T cells in mycosis fungoides and Sézary syndrome].
Iwahara K
Nihon Hifuka Gakkai Zasshi; 1984 Nov; 94(13):1499-507. PubMed ID: 6335535
[No Abstract] [Full Text] [Related]
6. [Mycosis fungoides and Sézary syndrome, so-called cutaneous T-cell lymphoma].
Rupniewska ZM
Postepy Hig Med Dosw; 1982; 36(4):231-49. PubMed ID: 6764803
[No Abstract] [Full Text] [Related]
7. How we treat mycosis fungoides and Sézary syndrome.
Khan N; Noor SJ; Horwitz S
Clin Adv Hematol Oncol; 2021 Sep; 19(9):573-581. PubMed ID: 34495021
[No Abstract] [Full Text] [Related]
8. The time for new biomarkers in mycosis fungoides/Sézary syndrome is here.
Ortiz-Romero PL
Br J Dermatol; 2021 Aug; 185(2):250-251. PubMed ID: 34096050
[No Abstract] [Full Text] [Related]
9. Unmasking mycosis fungoides/Sézary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course.
Foo SH; Shah F; Chaganti S; Stevens A; Scarisbrick JJ
Br J Dermatol; 2016 Apr; 174(4):901-4. PubMed ID: 26479768
[No Abstract] [Full Text] [Related]
10. Letter to the editor with regard to the article entitled "Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping".
Roelens M; de Masson A; Ram-Wolff C; Bagot M; Moins-Teisserenc H
Cytometry B Clin Cytom; 2021 Mar; 100(2):139-140. PubMed ID: 33031631
[No Abstract] [Full Text] [Related]
11. Lymph node histopathology in mycosis fungoides and Sézary's syndrome.
Scheffer E; Meijer CJ; Willemze R; van Vloten WA
Curr Probl Dermatol; 1990; 19():105-13. PubMed ID: 2404671
[No Abstract] [Full Text] [Related]
12. Non-Hodgkin Lymphoma: Examining Mycosis Fungoides and Sézary Syndrome in the Context of Oncology Nursing.
Ow KV; Brant JM
Clin J Oncol Nurs; 2021 Oct; 25(5):555-562. PubMed ID: 34533520
[TBL] [Abstract][Full Text] [Related]
13. [Item no 164: malignant lymphoma: cutaneous lymphoma].
CEDEF
Ann Dermatol Venereol; 2008 Nov; 135(11 Suppl):F160-2. PubMed ID: 18984207
[No Abstract] [Full Text] [Related]
14. Authors reply to the letter to editor with regard to the article titled "Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping".
Almeida J; Pulitzer MP; Horna P
Cytometry B Clin Cytom; 2021 Mar; 100(2):141. PubMed ID: 33166040
[No Abstract] [Full Text] [Related]
15. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
16. A high expression of cell adhesion molecule 1 (CADM1) is an unfavorable prognostic factor in mycosis fungoides.
Mashima E; Sawada Y; Yamaguchi T; Yoshioka H; Ohmori S; Haruyama S; Yoshioka M; Okada E; Nakamura M
Clin Immunol; 2018 Aug; 193():121-122. PubMed ID: 29391198
[No Abstract] [Full Text] [Related]
17. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
18. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
19. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
20. TMEM244 Gene Expression as a Potential Blood Diagnostic Marker Distinguishing Sézary Syndrome from Mycosis Fungoides and Benign Erythroderma.
Rassek K; Iżykowska K; Żurawek M; Nowicka K; Joks M; Olek-Hrab K; Olszewska B; Sokołowska-Wojdyło M; Biernat W; Nowicki RJ; Przybylski GK
J Invest Dermatol; 2023 Feb; 143(2):344-347.e3. PubMed ID: 36087622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
